Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003553 · ClinicalTrials.gov registry record · Phase 2
Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
A Phase 2 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT00003553 is a Phase 2 study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 156 participants.
The verdict
NCT00003553, a Phase 2 study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, before a donor peripheral blood stem cell transplant helps stop the growth of tumor cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining tumor cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine with or without mycophenolate mofetil or methotrexate after the transplant may stop this from happening. PURPOSE: This phase II trial is studying how well peripheral stem cell transplant works in treating patients with metastatic kidney cancer.
Interventions
- OTHER HLA Matched Peripheral BLood Stem Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 1998-02-09 |
| Est. Completion | 2011-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003553
The ClinicalTrials.gov registry entry for NCT00003553 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HLA Matched Peripheral BLood Stem Cells is the first listed.
NCT00003553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003553 about?
NCT00003553 is a clinical study titled "Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer". RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, before a donor peripheral blood stem cell transplant helps stop the growth of tumor cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the...
What is the current status of trial NCT00003553?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 1998-02-09. Estimated completion is 2011-06-27.
What interventions are being tested in trial NCT00003553?
The interventions under investigation include: HLA Matched Peripheral BLood Stem Cells (OTHER).
Who is sponsoring clinical trial NCT00003553?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.